Lung Therapeutics Overview
- Year Founded
-
2013
- Status
-
Acquired/Merged
- Employees
-
13
- Latest Deal Type
-
M&A
Lung Therapeutics General Information
Description
Developer of novel peptide drugs intended to facilitate treatments for fibrosis and lung conditions. The company's drugs trigger both survival signals for alveolar epithelial cells and destruction signals for unwanted fibrotic cells, enabling medical practitioners to treat idiopathic pulmonary fibrosis and loculated pleural effusion among other life-threatening lung diseases.
Contact Information
Website
www.lungtx.com(Operating Subsidiary)
Corporate Office
- 3801 South Capital of Texas Highway
- Suite 330
- Austin, TX 78704
- United States
Corporate Office
- 3801 South Capital of Texas Highway
- Suite 330
- Austin, TX 78704
- United States
Lung Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Merger/Acquisition | 31-Oct-2023 | Completed | Clinical Trials - Phase 2 | |||
| 11. Later Stage VC | 04-Apr-2022 | Completed | Clinical Trials - Phase 2 | |||
| 10. Grant | 21-Aug-2020 | Completed | Clinical Trials - Phase 1 | |||
| 9. Debt - PPP | 14-Apr-2020 | Completed | Clinical Trials - Phase 1 | |||
| 8. Later Stage VC (Series C) | 31-Oct-2019 | Completed | Clinical Trials - Phase 1 | |||
| 7. Early Stage VC (Series B) | 01-Mar-2016 | Completed | Clinical Trials - Phase 1 | |||
| 6. Grant | 27-Oct-2015 | Completed | Clinical Trials - Phase 1 | |||
| 5. Early Stage VC (Series A) | 10-Sep-2014 | Completed | Clinical Trials - Phase 1 | |||
| 4. Accelerator/Incubator | 12-Mar-2014 | Completed | Clinical Trials - Phase 1 | |||
| 3. Seed Round | 09-Sep-2013 | Completed | Clinical Trials - Phase 1 |
Lung Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A | 10,888,283 | $0.000100 | $0.02 | $0.27 | $0.27 | 1x | $0.27 | 12.06% |
Lung Therapeutics Comparisons
Industry
Financing
Details
Lung Therapeutics Competitors (21)
One of Lung Therapeutics’s 21 competitors is Moerae Matrix, a Formerly VC-backed company based in Morristown, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Moerae Matrix | Formerly VC-backed | Morristown, NJ | ||||
| Enterprise Therapeutics | Venture Capital-Backed | Brighton, United Kingdom | ||||
| hVIVO | Formerly VC-backed | London, United Kingdom | ||||
| Aqualung Therapeutics | Venture Capital-Backed | Tucson, AZ | ||||
| Galecto | Formerly VC-backed | Copenhagen, Denmark |
Lung Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Lung Therapeutics Patents
Lung Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2024071397-A | Modified peptide fragments of cav-1 protein and use thereof in treatment of fibrosis | Pending | 10-Sep-2018 | ||
| JP-2024114982-A | Dry powder formulation of caveolin-1 peptides and methods of use thereof | Pending | 10-Sep-2018 |
Lung Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Lung Therapeutics Former Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Austin Technology Incubator | Accelerator/Incubator | Minority | ||
| Bios Partners | Venture Capital | Minority | ||
| Chris Wang | Angel (individual) | Minority | ||
| DEFTA Partners | Venture Capital | Minority | ||
| Gus Johnson | Angel (individual) | Minority |
Lung Therapeutics FAQs
-
When was Lung Therapeutics founded?
Lung Therapeutics was founded in 2013.
-
Where is Lung Therapeutics headquartered?
Lung Therapeutics is headquartered in Austin, TX.
-
What is the size of Lung Therapeutics?
Lung Therapeutics has 13 total employees.
-
What industry is Lung Therapeutics in?
Lung Therapeutics’s primary industry is Drug Discovery.
-
Is Lung Therapeutics a private or public company?
Lung Therapeutics is a Private company.
-
What is Lung Therapeutics’s current revenue?
The current revenue for Lung Therapeutics is .
-
How much funding has Lung Therapeutics raised over time?
Lung Therapeutics has raised $65.8M.
-
Who are Lung Therapeutics’s investors?
Austin Technology Incubator, Bios Partners, Chris Wang, DEFTA Partners, and Gus Johnson are 5 of 14 investors who have invested in Lung Therapeutics.
-
Who are Lung Therapeutics’s competitors?
Moerae Matrix, Enterprise Therapeutics, hVIVO, Aqualung Therapeutics, and Galecto are some of the 21 competitors of Lung Therapeutics.
-
When was Lung Therapeutics acquired?
Lung Therapeutics was acquired on 31-Oct-2023.
-
Who acquired Lung Therapeutics?
Lung Therapeutics was acquired by Aileron Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
